Pearl Therapeutics finds $15.5M in first VC round

Upstart Pearl Therapeutics, which is developing therapies for respiratory disorders, has raised $15.5 million in its first round. The Redwood City, CA-based biotech's round was co-led by New Leaf Ventures and Clarus Ventures with 5AM Ventures as a major participant. Pearl has in-licensed a suite of particle technologies from Nektar Therapeutics. The biotech was co-founded by two former members of Nektar's corporate and product development organizations.

- check out the release

ALSO: San Diego-based Cyntellect has completed a $3 million second closing on its Series D round. This closing follows the initial Series D closing of $15.1 million. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.